Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 78 articles: HTML format

Single Articles

April 2024
1. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
   Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
   J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
   PubMed     Abstract available
   
   
   
2. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
   Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
   J Gastroenterol. 2024;59:329-341.
   PubMed     Abstract available
   
   
   March 2024
3. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
   Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
   J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
   PubMed     Abstract available
   
   
   
4. WANG J, Zhang H, Chen L, Fu K, et al
   CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
   J Gastroenterol. 2024;59:229-249.
   PubMed     Abstract available
   
   
   February 2024
5. WU C, Li J, Jia H, Zhao J, et al
   Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
   J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
   PubMed     Abstract available
   
   
   
6. NAMISAKI T, Sato S, Yoshiji H
   Role of combined aerobic and resistance exercise in liver cirrhosis.
   J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
   PubMed    
   
   
   January 2024
7. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
   Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
   J Gastroenterol. 2024;59:56-65.
   PubMed     Abstract available
   
   
   
8. HANAI T, Nishimura K, Unome S, Miwa T, et al
   A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
   J Gastroenterol. 2024;59:45-55.
   PubMed     Abstract available
   
   
   December 2023
9. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
   Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
   J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
   PubMed     Abstract available
   
   
   
10. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    PubMed    
    
    
    
11. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    PubMed    
    
    
    November 2023
12. YANG Z, Shi M, Liang Y, Zhang F, et al
    Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
    J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
    PubMed     Abstract available
    
    
    October 2023
13. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    PubMed     Abstract available
    
    
    
14. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed     Abstract available
    
    
    
15. CRANE H, Gofton C, Sharma A, George J, et al
    MAFLD: an optimal framework for understanding liver cancer phenotypes.
    J Gastroenterol. 2023;58:947-964.
    PubMed     Abstract available
    
    
    September 2023
16. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
    Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
    J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
    PubMed     Abstract available
    
    
    
17. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    PubMed    
    
    
    
18. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    PubMed     Abstract available
    
    
    
19. LIU C, Zhu S, Zhang J, Wu P, et al
    Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
    J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
    PubMed     Abstract available
    
    
    August 2023
20. YANG L, Tian S, Zheng X, Zhang M, et al
    N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.
    J Gastroenterol. 2023;58:718-733.
    PubMed     Abstract available
    
    
    
21. TADA F, Hiraoka A, Tada T, Hirooka M, et al
    Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
    J Gastroenterol. 2023 Aug 1. doi: 10.1007/s00535-023-02026.
    PubMed     Abstract available
    
    
    July 2023
22. XIE C, Ye X, Zeng L, Zeng X, et al
    Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
    J Gastroenterol. 2023 Jul 27. doi: 10.1007/s00535-023-02011.
    PubMed     Abstract available
    
    
    
23. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    PubMed     Abstract available
    
    
    
24. LI L, Wu PS, Liang XM, Chen K, et al
    Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.
    J Gastroenterol. 2023 Jul 14. doi: 10.1007/s00535-023-02018.
    PubMed     Abstract available
    
    
    
25. PENG M, Li H, Cao H, Huang Y, et al
    Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2023 Jul 11. doi: 10.1007/s00535-023-02012.
    PubMed     Abstract available
    
    
    
26. CHEN G, Zhu W, Liu Y, Zhang L, et al
    The clonal heterogeneity of colon cancer with liver metastases.
    J Gastroenterol. 2023;58:642-655.
    PubMed     Abstract available
    
    
    June 2023
27. XU H, Lin X, Li Z, He X, et al
    VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    J Gastroenterol. 2023 Jun 30. doi: 10.1007/s00535-023-02015.
    PubMed     Abstract available
    
    
    May 2023
28. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    PubMed     Abstract available
    
    
    
29. UENO M, Fujiwara T, Tokumasu H, Mano T, et al
    Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan.
    J Gastroenterol. 2023 May 12. doi: 10.1007/s00535-023-02000.
    PubMed     Abstract available
    
    
    
30. YE MP, Lu WL, Rao QF, Li MJ, et al
    Mitochondrial stress induces hepatic stellate cell activation in response to the ATF4/TRIB3 pathway stimulation.
    J Gastroenterol. 2023 May 7. doi: 10.1007/s00535-023-01996.
    PubMed     Abstract available
    
    
    April 2023
31. NAKAI M, Morikawa K, Sasaki T, Kohya R, et al
    Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    J Gastroenterol. 2023 Apr 27. doi: 10.1007/s00535-023-01993.
    PubMed     Abstract available
    
    
    March 2023
32. YAMAUCHI R, Ito T, Yoshio S, Yamamoto T, et al
    Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2023 Mar 30. doi: 10.1007/s00535-023-01985.
    PubMed     Abstract available
    
    
    
33. GAO TM, Zhou J, Xiang XX, Jin SJ, et al
    plenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.
    J Gastroenterol. 2023 Mar 21. doi: 10.1007/s00535-023-01982.
    PubMed     Abstract available
    
    
    
34. CHANG X, Li Y, Sun C, Li X, et al
    High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2023 Mar 16. doi: 10.1007/s00535-023-01970.
    PubMed     Abstract available
    
    
    
35. FU Y, Peng W, Zhang W, Yang Z, et al
    Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    J Gastroenterol. 2023 Mar 9. doi: 10.1007/s00535-023-01976.
    PubMed     Abstract available
    
    
    
36. MA L, Liu Y, Yan Z, Zhang W, et al
    Comparing the predictive ability of portoatrial and portocaval gradient after transjugular intrahepatic portosystemic shunt creation for variceal rebleeding.
    J Gastroenterol. 2023 Mar 9. doi: 10.1007/s00535-023-01977.
    PubMed     Abstract available
    
    
    February 2023
37. KOTANI K, Enomoto M, Uchida-Kobayashi S, Tamori A, et al
    Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    J Gastroenterol. 2023 Feb 2. doi: 10.1007/s00535-023-01963.
    PubMed     Abstract available
    
    
    
38. KAMADA Y, Nakamura T, Isobe S, Hosono K, et al
    SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.
    J Gastroenterol. 2023;58:79-97.
    PubMed     Abstract available
    
    
    
39. TSUGE M, Kawaoka T, Oka S
    Factors for the recurrence of hepatocellular carcinoma after hepatic resection.
    J Gastroenterol. 2023 Feb 1. doi: 10.1007/s00535-023-01962.
    PubMed    
    
    
    January 2023
40. ZHANG X, Durham KM, Garza AA, Murali AR, et al
    Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension.
    J Gastroenterol. 2023 Jan 24. doi: 10.1007/s00535-023-01957.
    PubMed     Abstract available
    
    
    
41. NAKAYAMA H, Okamura Y, Higaki T, Moriguchi M, et al
    Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis.
    J Gastroenterol. 2023 Jan 2. doi: 10.1007/s00535-022-01946.
    PubMed     Abstract available
    
    
    
42. SAKAI N, Kamimura K, Miyamoto H, Ko M, et al
    Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17beta-hydroxysteroid dehydrogenase 13 expression.
    J Gastroenterol. 2023;58:53-68.
    PubMed     Abstract available
    
    
    December 2022
43. ISHIKAWA T, Egusa M, Fujioka T, Nishiyama N, et al
    A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension.
    J Gastroenterol. 2022 Dec 30. doi: 10.1007/s00535-022-01947.
    PubMed     Abstract available
    
    
    
44. SATAKE T, Morizane C, Rikitake R, Higashi T, et al
    Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry.
    J Gastroenterol. 2022 Dec 23. doi: 10.1007/s00535-022-01944.
    PubMed    
    
    
    November 2022
45. LIN YC, Lin HF, Wu CC, Chen CL, et al
    Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity.
    J Gastroenterol. 2022;57:913-925.
    PubMed     Abstract available
    
    
    September 2022
46. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.
    J Gastroenterol. 2022 Sep 29. pii: 10.1007/s00535-022-01925.
    PubMed     Abstract available
    
    
    
47. SATAKE T, Morizane C, Rikitake R, Higashi T, et al
    The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry.
    J Gastroenterol. 2022 Sep 26. pii: 10.1007/s00535-022-01920.
    PubMed     Abstract available
    
    
    August 2022
48. ZHOU Q, Wang X, Li R, Wang C, et al
    Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Aug 3. pii: 10.1007/s00535-022-01910.
    PubMed    
    
    
    July 2022
49. KODAMA K, Kawaoka T, Kosaka M, Johira Y, et al
    Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
    J Gastroenterol. 2022 Jul 18. pii: 10.1007/s00535-022-01887.
    PubMed     Abstract available
    
    
    
50. ZHOU Q, Wang X, Li R, Wang C, et al
    Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Jul 11. pii: 10.1007/s00535-022-01895.
    PubMed     Abstract available
    
    
    
51. LIU T, Liao S, Mo J, Bai X, et al
    LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.
    J Gastroenterol. 2022 Jul 8. pii: 10.1007/s00535-022-01901.
    PubMed     Abstract available
    
    
    
52. OKUSHIN K, Tateishi R, Takahashi A, Uchino K, et al
    Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
    J Gastroenterol. 2022 Jul 5. pii: 10.1007/s00535-022-01893.
    PubMed     Abstract available
    
    
    June 2022
53. KARIYAMA K, Hiraoka A, Kumada T, Yasuda S, et al
    Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
    J Gastroenterol. 2022 Jun 28. pii: 10.1007/s00535-022-01883.
    PubMed     Abstract available
    
    
    May 2022
54. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    PubMed     Abstract available
    
    
    April 2022
55. NISHIDA N, Yamakawa M, Shiina T, Mekada Y, et al
    Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.
    J Gastroenterol. 2022;57:309-321.
    PubMed     Abstract available
    
    
    
56. IRITANI S, Kawamura Y, Muraishi N, Fujiyama S, et al
    The useful predictors of zinc deficiency for the management of chronic liver disease.
    J Gastroenterol. 2022;57:322-332.
    PubMed     Abstract available
    
    
    March 2022
57. SUZUKI Y, Mori T, Momose H, Matsuki R, et al
    Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.
    J Gastroenterol. 2022 Mar 31. pii: 10.1007/s00535-022-01868.
    PubMed     Abstract available
    
    
    
58. LIN W, Lin J, Li J, Lin Y, et al
    Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.
    J Gastroenterol. 2022 Mar 4. pii: 10.1007/s00535-022-01866.
    PubMed     Abstract available
    
    
    February 2022
59. WANG XH, Hu ZL, Fu YZ, Hou JY, et al
    Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    J Gastroenterol. 2022 Feb 13. pii: 10.1007/s00535-022-01855.
    PubMed     Abstract available
    
    
    January 2022
60. SAKAMORI R, Yamada R, Tahata Y, Kodama T, et al
    The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
    J Gastroenterol. 2022 Jan 22. pii: 10.1007/s00535-021-01842.
    PubMed     Abstract available
    
    
    
61. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    PubMed     Abstract available
    
    
    
62. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    PubMed     Abstract available
    
    
    December 2021
63. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    PubMed     Abstract available
    
    
    
64. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    PubMed     Abstract available
    
    
    
65. KAMADA Y, Takahashi H, Shimizu M, Kawaguchi T, et al
    Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.
    J Gastroenterol. 2021;56:1045-1061.
    PubMed     Abstract available
    
    
    November 2021
66. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    PubMed     Abstract available
    
    
    
67. YONEDA M, Yamamoto T, Honda Y, Imajo K, et al
    Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    J Gastroenterol. 2021;56:1022-1032.
    PubMed     Abstract available
    
    
    September 2021
68. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    PubMed     Abstract available
    
    
    
69. TOKUSHIGE K, Ikejima K, Ono M, Eguchi Y, et al
    Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01796.
    PubMed     Abstract available
    
    
    July 2021
70. LI D, Ding X, Tian D, Xia L, et al
    Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
    J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.
    PubMed    
    
    
    
71. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available
    
    
    
72. SUMIDA Y, Yoneda M
    COVID-19-associated liver injury (COVALI): role of hepatologists.
    J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.
    PubMed    
    
    
    May 2021
73. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
    Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
    PubMed     Abstract available
    
    
    January 2021
74. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.
    PubMed    
    
    
    
75. GARCIA-VILLARREAL L, Hernandez-Ortega A, Sanchez-Monteagudo A, Pena-Quintana L, et al
    Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.
    J Gastroenterol. 2021;56:78-89.
    PubMed     Abstract available
    
    
    
76. JIANG L, Starkel P, Fan JG, Fouts DE, et al
    The gut mycobiome: a novel player in chronic liver diseases.
    J Gastroenterol. 2021;56:1-11.
    PubMed     Abstract available
    
    
    August 2020
77. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    PubMed     Abstract available
    
    
    December 2019
78. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.